Company News-宜明昂科英文

2025-10-31

Positive Progress of Amulirafusp Alfa (IMM0306) in the Treatment of Systemic Lupus Erythematosus (SLE) Presented at ACR Convergence 2025

On October 28, 2025, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as "ImmuneOnco," with the stock code 01541.HK on the Hong Kong Stock Exchange) presented the latest results of the Phase

2025-10-02

Application for Phase III Clinical Trial of IMM2510 for IO-Resistant Non-Small Cell Lung Cancer Submitted to CDE

2025-09-17

Application for the Phase III Clinical Trial of IMM0306 for the Treatment of Follicular Lymphoma

2025-09-16

Important Milestone | IMM2510 (VEGF×PD-L1) Two Phase III Registration Clinical Trials Have Submitted EOP2 Innovative Therapy Enters Key Stage

IMM2510 has submitted End-of-Phase 2 (EOP2) communication applications for two Phase III registration clinical trials targeting different types of lung cancer to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).

2025-09-09

IMM2510 Shows Breakthrough Potential in IO-Resistant Squamous NSCLC at WCLC 2025

IMM2510, an Anti-PD-L1/VEGF Bispecific Antibody Fusion Protein for Advanced IO-treated SQ-NSCLC: A Phase I Study